Listed by the USPTO as WARD, PAUL V
Tech Center 1600 • Art Units: 1622 1624
This examiner grants 83% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18804699 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 18797142 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Non-Final OA | Novartis AG |
| 18475520 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING LIGHT-EMITTING DEVICE | Non-Final OA | Samsung Display Co., Ltd. |
| 18532671 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18799303 | PTPN11 INHIBITORS | Non-Final OA | Board of Regents, The University of Texas System |
| 18559805 | COMPOSITION COMPRISING AHAS AND/OR BHAS WHICH IS STABILIZED BY A COMBINATION OF MONOALKYL OR DIALKYL ISOSORBIDE, POLYETHYLENE GLYCOL-POLYPROPYLENE GLYCOL ETHER AND TWO HYDROGENATED OR NON-HYDROGENATED POLYOXYETHYLENATED PLANT OILS | Non-Final OA | L'OREAL |
| 18176420 | ALKYLENE OXIDE DERIVATIVES, WETTING AGENT, SOLUBILIZING AGENT, AND SOLUBILIZING COMPOSITION | Non-Final OA | NOF CORPORATION |
| 18553870 | INSANITARY INSECT PEST CONTROL METHOD USING CONDENSED HETEROCYCLIC COMPOUND | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18866777 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | Non-Final OA | NUVATION BIO INC. |
| 18901169 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC | Non-Final OA | Actinium Pharmaceuticals, Inc. |
| 18833008 | METAP2 INHIBITORS AND USES THEREOF | Non-Final OA | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy83.2% of resolved applications examined by Paul V Ward were allowed (1,707 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is -12.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Paul V Ward took 858 days on average from filing to allowance.
Paul V Ward examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
